JW55

Description

JW 55 is an inhibitor of the PARP domain of tankyrases (TNKS) 1 and 2 (IC₅₀s = 1.9 and 0.83 μM, respectively). By inhibiting TNKS1/2, JW 55 stabilizes Axin2 and increases degradation of β-catenin, inhibiting the β-catenin signaling pathway (IC₅₀ = 470 nM). It has been shown to decrease canonical Wnt signaling in SW480 and HCT15 colon carcinoma cell lines and to reduce proliferation of SW480 cells in vitro.

The Uses of JW55

JW-55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). Activity results in stabilization of Axin2 and increased degradation of β-catenin. JW-55 inhibits the β-catenin signaling pathway. Also shown to decrease canonical Wnt signaling in SW480 and HCT-15 colon carcinoma cell lines. JW-55 reduces cell cycle progression and proliferation in SW480 cells in vitro.

What are the applications of Application

JW 55 is an inhibitor of the PARP domain and beta-catenin pathway

Definition

ChEBI: N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamide is a member of furans and an aromatic amide.

Storage

Store at +4°C

References

[1] waaler j, machon o, tumova l, dinh h, korinek v, wilson sr, paulsen je, pedersen nm, eide tj, machonova o, gradl d, voronkov a, von kries jp, krauss s. a novel tankyrase inhibitor decreases canonical wnt signaling in colon carcinoma cells and reduces tumor growth in conditional apc mutant mice. cancer res. 2012;72(11):2822-32.